Royalty Pharma's stock has experienced a significant upward trend according to top brokers. Notably,
TD Cowen has raised the stock price target to $50, citing growth as the key reason. The stock hit a
52-week high three times, showing its strong market performance.
Vanguard Group and
Aberdeen Group sold and bought shares of Royalty Pharma respectively, signifying different investment strategies by top asset management companies. In a series of news, continued share buybacks and steady financial performance have seen the company's analysts retain a positive stance on the stock.
Royalty Pharma offered guidance for 2026, involving strong portfolio growth and updated earnings. In a unique deal,
Denali and Royalty Pharma entered a $275M funding agreement. Reassuringly, their
Q4 earnings surpassed estimates, which contributed to the bullish holding of stocks amidst insider sales. There have been some notable sales by CFO-linked entities and top executives, indicating mixed insider confidence. However, the
increase in dividend, impressive Q4 earnings, and initiation of a buy rating by
Goldman Sachs all point to attractive growth for investors.
Royalty Pharma Stocks News Analytics from Fri, 29 Aug 2025 07:00:00 GMT to Fri, 27 Feb 2026 21:37:41 GMT -
Rating 7
- Innovation 2
- Information 6
- Rumor -2
